Press Releases July 24, 2026 06:50 AM

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

ANI Pharmaceuticals schedules Q2 2026 financial results webcast for August 7, 2026

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ANIP

ANI Pharmaceuticals, Inc. announced that it will release its second quarter 2026 financial results on August 7, 2026, and host a webcast with senior management to discuss the results. The company is a diversified biopharmaceutical firm focusing on rare diseases, generics, and brand pharmaceuticals.

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
ANIP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • ANI Pharmaceuticals to report Q2 2026 earnings on August 7, 2026, with a webcast featuring top executives.
  • The company operates three main business segments: Rare Disease products, Generics leveraging U.S.-based manufacturing, and Brand pharmaceuticals.
  • ANI's Rare Disease segment covers therapeutic areas including ophthalmology, rheumatology, nephrology, neurology, and pulmonology.

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.

To view the webcast, please click here. Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: [email protected]

Media Relations:
Argot Partners
T: 212-600-1494
E: [email protected]

SOURCE: ANI Pharmaceuticals, Inc.


Risks

  • Financial results may differ from market expectations, introducing volatility in the stock price post-release.
  • The biopharmaceutical sector faces regulatory, competitive, and market adoption risks affecting company performance.
  • Dependence on niche rare disease markets may pose risks in patient adoption and reimbursement uncertainties.

More from Press Releases

Micropolis Robotics Brings UAE-Developed Physical AI to the Annual Investment Meeting 2026 Sep 7, 2026 Kaltura to Showcase AI-Powered Media and Telecom Innovations at IBC 2026, Spanning Customer Care Avatars, Sports Discovery, and Personalized Streaming Experiences Sep 7, 2026 Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 Sep 7, 2026 Digital Realty Strengthens Nairobi as East Africa Digital Gateway with New Data Center Sep 7, 2026 Teva Announces Launch of Offering of Senior Notes Sep 7, 2026